MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis

2012 ◽  
Vol 18 (9) ◽  
pp. 1337-1339 ◽  
Author(s):  
Luigi ME Grimaldi ◽  
Luca Prosperini ◽  
Gaetano Vitello ◽  
Giovanna Borriello ◽  
Federica Fubelli ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Therapeutic Window ◽  
Resonance Imaging ◽  
Therapy Discontinuation ◽  
Dosing Interval ◽  
Relapsing Remitting ◽  
Mri Scans ◽  
Magnetic Resonance Imaging Mri

The recommended natalizumab dosage is 300 mg every 4 weeks. We evaluated radiological activity at various times from the last natalizumab infusion by examining 386 magnetic resonance imaging (MRI) scans from 166 natalizumab-treated patients with relapsing–remitting MS. Of 113 scans performed >4 weeks after last natalizumab infusion, 26 were active (i.e. had ≥1 contrast-enhancing lesions). Risk of radiological activity increased by 1.34 fold for each week of delay with respect to the recommended 4-week dosing interval, compared with schedule-adherent patients ( p<0.0001). Our data suggest that an increased MRI activity ≥7 weeks from the last infusion of natalizumab should be considered in cases of therapy discontinuation.

Application of Artificial Intelligence in Magnetic Resonance Imaging to reduce Gadolinium accumulation in patients with multiple sclerosis: A Review

2021 ◽  
Vol 1 (4) ◽  
pp. 416-428
Author(s):  
Vijay Anant Athavale ◽  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Artificial Intelligence ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Resonance Imaging ◽  
Mri Scans ◽  
The Central Nervous System ◽  
Magnetic Resonance Imaging Mri ◽  
The Brain ◽  
New Onset

Gadolinium (Gd) is a based contrast agent is used for Magnetic Resonance Imaging (MRI). In India, gadobutrolhas been is approved for MRI of the Central Nervous System (CNS), liver, kidneys, and breast. It has been noted in several studies that the accumulation of gadolinium occurs in different structures in the brain. Patients with Multiple Sclerosis (MS) are regularly followed up with MRI scans and MRI with contrast enhancement is the most common method of distinguishing new-onset pathological changes. Developments in technology and methods in artificial intelligence have shown that there is reason to map out the X-ray technician’s work with examinations and medicines administered to patients may be altered to prevent the accumulation of gadolinium.

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials

1997 ◽  
Vol 2 (6) ◽  
pp. 283-290 ◽  
Author(s):  
L Truyen ◽  
F Barkhof ◽  
M Tas ◽  
MAA Van Walderveen ◽  
STFM Frequin ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Median Number ◽  
Specific Power ◽  
Resonance Imaging ◽  
Power Calculations ◽  
Relapsing Remitting ◽  
Magnetic Resonance Imaging Mri ◽  
Trial Monitoring

Inhomogeneous patient samples have been used in previous studies to determine the power of magnetic resonance imaging (MRI) for trial monitoring in multiple sclerosis (MS). These power-calculations might not be applicable to the active relapsing-remitting patient who is preferably included in trials. In order to reevaluate the power alculations for MRI in the monitoring of treatment in strictly relapsing-remitting MS and to compare the power of different trial designs we studied 12 relapsing-remitting MS patients prospectively for a median period of II months using monthly clinical assessments and gadolinium-enhanced MRI. A median number of two clinical relapses/patient occurred of which a median of one was treated with steroids. A median of 1.59 new lesions/scan/patient was detected (range 0–8). The total number of new active lesions correlated significantly with study period relapses (SRCC=0.72, P=0.023). Computer simulations using the bootstrap technique yielded mostly lower power values for a parallel groups design than in previous studies except for short follow-periods in larger samples. In this sample the open cross-over design was found to be between 20 and 40% more powerful. Results of power-calculations are clearly sample dependent implying that for treatment trial monitoring using MRI in relapsing-remitting MS conservative sample size estimates are to be used. In an active patient group open cross-over trial designs could be a very powerful alternative to parallel groups design.

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis

2005 ◽  
Vol 11 (4) ◽  
pp. 447-449 ◽  
Author(s):  
M P Sormani ◽  
P Bruzzi ◽  
G Comi ◽  
M Filippi
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Glatiramer Acetate ◽  
Resonance Imaging ◽  
Relapsing Remitting ◽  
Patient Heterogeneity ◽  
Magnetic Resonance Imaging Mri ◽  
Using Data ◽  
Measured Response

We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing=remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.

Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients

2005 ◽  
Vol 11 (3) ◽  
pp. 282-285 ◽  
Author(s):  
C J da Silva ◽  
A J da Rocha ◽  
M F Mendes ◽  
A CM Maia ◽  
F T Braga ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Clinical Correlation ◽  
Resonance Imaging ◽  
Root Entry Zone ◽  
Mri Scans ◽  
Trigeminal Root ◽  
Peripheral Type ◽  
Magnetic Resonance Imaging Mri

Trigeminal involvement detected by magnetic resonance imaging (MRI) in multiple sclerosis (MS) patients is usually associated with trigeminal neuralgia (TN) or painless paraesthesia in the trigeminal distribution. Our aim is to review the incidence of trigeminal involvement on MRI in a series of patients with MS at our institution, with further clinical correlation. We reviewed MRI scans of 275 MS patients for the presence of gadolinium enhancement on postcontrast T1-weighted images, anatomical and signal abnormalities on different sequences at the pontine trigeminal root entry zone (REZ) and in the cisternal portion of the nerves. We observed enhancement in the cisternal portion of the nerves and signal abnormalities (with or without enhancement) at the pontine trigeminal REZ in 8 (2.9%) patients, and enhancement was bilateral in 6 (75%) of those. Despite the inflammatory activity, none of them had TN and 3 (37.5%) had only painless paraesthesias in the correspondent V3 distribution. We also found a marked trigeminal hypertrophy in 2 (25%) patients, both with a longer period of disease. Our results confirm a high and clinically silent incidence of trigeminal involvement in MS patients, and suggest a simultaneous role of the central and peripheral type of myelin in trigeminal demyelination.

scholarly journals Magnetic resonance imaging (MRI) scans in patients with dorsal root ganglion stimulation

Pain Practice ◽  
2021 ◽  
Author(s):  
Marco Reining ◽  
Dirk Winkler ◽  
Joachim Boettcher ◽  
Juergen Meixensberger ◽  
Michael Kretzschmar
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Dorsal Root Ganglion ◽  
Dorsal Root ◽  
Resonance Imaging ◽  
Mri Scans ◽  
Magnetic Resonance Imaging Mri
Sign in / Sign up

Export Citation Format

Share Document